An uncommon t(9;11)(p24;q22) with monoallelic loss of ATM and KMT2A genes in a child with myelodysplastic syndrome/acute myeloid leukemia who evolved from Fanconi anemia
- 359 Downloads
Myelodysplastic syndrome (MDS) is rare in the pediatric age group and it may be associated with inheritable bone marrow failure (BMF) such as Fanconi anemia (FA). FA is a rare multi-system genetic disorder, characterized by congenital malformations and progressive BMF. Patients with FA usually present chromosomal aberrations when evolving to MDS or acute myeloid leukemia (AML). Thus, the cytogenetic studies in the bone marrow (BM) of these patients have an important role in the therapeutic decision, mainly in the indication for hematopoietic stem cell transplantation (HSCT). The most frequent chromosomal alterations in the BM of FA patients are gains of the chromosomal regions 1q and 3q, and partial or complete loss of chromosome 7. However, the significance and the predictive value of such clonal alterations, with respect to malignant progress, are not fully understood and data from molecular cytogenetic studies are very limited.
A five-year-old boy presented recurrent infections and persistent anemia. The BM biopsy revealed hypocellularity. G-banding was performed on BM cells and showed a normal karyotype. The physical examination showed to be characteristic of FA, being the diagnosis confirmed by DEB test. Five years later, even with supportive treatment, the patient presented severe hypocellularity and BM evolution revealing megakaryocyte dysplasia, intense dyserythropoiesis, and 11% myeloblasts. G-banded analysis showed an abnormal karyotype involving a der(9)t(9;11)(p24;q?22). The FISH analysis showed the monoallelic loss of ATM and KMT2A genes. At this moment the diagnosis was MDS, refractory anemia with excess of blasts (RAEB). Allogeneic HSCT was indicated early in the diagnosis, but no donor was found. Decitabine treatment was initiated and well tolerated, although progression to AML occurred 3 months later. Chemotherapy induction was initiated, but there was no response. The patient died due to disease progression and infection complications.
Molecular cytogenetic analysis showed a yet unreported der(9)t(9;11)(p24;q?22),der(11)t(9;11)(p24;q?22) during the evolution from FA to MDS/AML. The FISH technique was important allowing the identification at the molecular level of the monoallelic deletion involving the KMT2A and ATM genes. Our results suggest that this chromosomal alteration conferred a poor prognosis, being associated with a rapid leukemic transformation and a poor treatment response.
KeywordsMyelodysplastic syndrome Acute myeloid leukemia Fanconi anemia Classical cytogenetics FISH T(9;11) ATM KMT2A
Acute myeloid leukemia
Ataxia Telangiectasia Mutated gene
Bone marrow failure
Cyclin-dependent kinase inhibitor 2A
- DAB2IP DAB2
- FA-BCRA DNA
Fanconi anemia complementation
Fluorescence in situ hybridization
Formin binding protein 1
Granulocyte-colony stimulating factor
Hematopoietic stem cell transplantation
- ICLs DNA
Janus kinase 2
Lysine methyltransferase 2A
Super elongation complex subunit
Paired related homeobox 2
PC4 and SFRS1 interacting protein 1
Refractory anemia with excess of blast
Myelodysplastic syndrome (MDS) comprises a heterogeneous group of clonal neoplastic blood diseases characterized by ineffective hematopoiesis, peripheral cytopenias, bone marrow dysplasias and an increased risk of acute myeloid leukemia (AML) . Pediatric MDS is an uncommon disorder accounting for 4–9% of hematologic malignancies [2, 3] and it may be associated with inherited bone marrow failure (BMF) disorders such as Fanconi Anemia (FA) .
First described in 1920 by the pediatrician Guido Fanconi , nowadays, it is known that FA is a cancer-prone chromosomal instability disorder with diverse clinical symptoms. The congenital anomalies may include skeletal defects, classically abnormal thumb or radius, short stature, café-au-lait spots and endocrinopathies. FA is a rare autosomal and X-linked genetic disease, with a wide variety of symptoms, characterized by congenital abnormalities, progressive BMF and increased cancer risk, which can be difficult to diagnose [5, 6, 7].
At the molecular level, 21 FA-related genes that constitute FA-BRCA pathway were identified . Proteins encoded by FA-related genes play important roles in various cellular functions, including DNA repair, detoxification of reactive oxygen species and aldehydes, energy metabolism and both pro-inflammatory and myelosuppressive cytokine homeostasis .
Since the first clinical report of FA, important laboratory and clinical advances were incorporated in the diagnosis and treatment, such as the DEB test and the application of HSCT, with a low dosage chemotherapy regimen for children with FA [9, 10, 11].
Supportive care using hematopoietic growth factors such as EPO, G-CSF or androgens such as oxymetholone to boost blood cell production, provides transient benefit in some patients. Although, the allogeneic HSCT remains the main treatment approach to advanced marrow failure in FA patients [11, 12]. In this context, some preclinical studies using gene therapy in an attempt to improve the life quality and survival of patients with FA have been performed .
Cytogenetic studies in the bone marrow have an important role in the therapeutic decision, mainly in the indication for HSCT. A better understanding of the clinical relevance and biological implications of clonal chromosomal alterations in FA patients was achieved over the last decade by the incorporation of molecular cytogenetic technologies in addition to classical karyotyping [11, 13]. This has led to the identification of some specific chromosomal alterations in FA patients, their prognostic value and association with the risk of evolution to MDS and/or AML. The most frequent chromosomal alterations in bone marrow of patients with FA are gains of the chromosomal regions 1q and 3q, and partial or complete loss of chromosome 7. Besides, monosomy 7 and del(7q) have been associated with poor prognosis and progression to leukemia. A few reports also suggested that gains of 3q are associated with progression to MDS/AML and overall presenting poor prognosis [13, 14].
Alterations involving del(11q) are uncommon in FA and MDS, so the prognostic value of this alteration remains uncertain [13, 15]. In this region, there are genes such as Ataxia Telangiectasia Mutated gene [ATM (11q22)] and lysine methyltransferase 2A [KMT2A (11q23)] that have been described as having an important role in the pathogenesis of MDS. The ATM gene acts on the regulation of the cell cycle after a DNA damage is recognized [15, 16]. On the other hand, the KMT2A gene encodes a protein that is involved in chromatin remodeling and positively regulates multiple homeobox transcription factors, also it is highly associated with the development of AML .
Given the high incidence of hematological complications of FA patients, BM surveillance for morphological and cytogenetic changes provides an important contribution to the clinical decision . However, there are only a few studies in patients with FA showing the bone marrow chromosomal alterations analyzed by classical and molecular cytogenetics associated with evolution to MDS and AML [13, 14, 17, 18, 19]. Here, we describe an uncommon yet unreported t(9;11)(p24;q22) with monoallelic loss of ATM and KMT2A genes, defined by classical cytogenetic and FISH analysis, in a child with MDS/AML who evolved from FA associated with poor clinical outcome.
Discussion and conclusions
Bone marrow failure occurs with a median age of 8 years and remains the primary cause of morbidity and mortality in FA . The FA cells have a reduced fidelity in processing DNA double-strand breaks. This specific intrinsic susceptibility might, together with extrinsic factors, influence the course of the disease, resulting in the outgrowth of clones with chromosomal aberrations in the bone marrow cells . Nevertheless, there is a cytogenetic clonal fluctuation in patients with FA, since clones often can disappear, reappear, evolve or be replaced by entirely new clones . Therefore, the significance and the predictive value of such clonal alterations with respect to malignant progress are not fully understood .
Rochowski et al., (2012) hypothesized that unique bone marrow cytogenetic clones may distinguish patients with FA and AML from patients with de novo AML. Some chromosomal abnormalities as the gain of 1q, 3q, 13q and partial loss of 7q, 20q, 11q or complete loss of chromosome 7 are more frequent in patients with FA who showed progression to AML. While others like trisomy 8, t(8;21), t(9;11), t(6;9) and inv.(16) have been described exclusively in patients with de novo AML . In this study, the t(9;11) was described in MDS/AML secondary from FA. Nevertheless, it is important to note that the breakpoints involved in this chromosomal translocation were not yet reported [22, 23]. In literature, the recurrent breakpoints involved in the t(9;11) in de novo AML patients were: t(9;11)(q34;q23) with FNBP1/KMT2A gene rearrangement ; t(9;11)(q34;p15) with NUP98/PRRX2 ; t(9;11)(q34;q23) with AF9q34/MLL  t(9;11)(p22;p15) with NUP98/PSIP1 ; and t(9;11)(p21;q23) with MLLT3/KMT2A ; t(9;11)(q34;q23) with DAB2IP/KMT2A .
In our study, the patient with FA showed the acquisition of a der(9)t(9;11)(p24;q?22), der(11)t(9;11)(p24;q?22) associated with evolution from MDS to AML. In FISH analysis, it was detected the monoallelic loss of ATM gene. The ATM gene is located at 11q22 region. This gene encodes a serine/threonine protein kinase, a critical enzyme in the regulation of the stress response to DNA damage, especially double-strand DNA breaks and it is also involved in cell cycle control. The ATM gene appears to act as a “caretaker” of the genome . The loss of ATM has been described as having contributed to the increased need for transfusion in patients with MDS associated with del(11q) . Currently, it has been demonstrated the joint and reciprocal action of ATM and FA proteins in the DNA repair pathway during replication [30, 31].
In our study, the FISH analysis also showed the monoallelic loss of the KMT2A gene. The KMT2A locus is involved in more than 60 different chromosomal translocations in pediatric acute leukemias . In AML, the t(9;11) usually results from KMT2A gene translocation, being the (p22;q23) the breakpoint frequently described . Interestingly, it was detected the monoallellic deletion of KMT2A gene in our study. Wang et al. showed that deletions of chromosome 11q lack cryptic KMT2A rearrangements in patients with MDS and suggested that loss of tumor suppressor genes located in 11q through deletions and secondary allelic loss of heterozygosity is likely more important in pathogenesis and disease progression . The detection of all possible types of KMT2A cyto-molecular abnormalities is of key importance for the identification of biological subgroups, which may differ in clinical outcome .
In the literature, data on FISH studies in FA are quite limited . In our study, the analysis by the FISH technique was essential allowing the identification at the molecular level of the monoallelic deletion involving the KMT2A and ATM genes. With the FISH results it was possible to note that this chromosomal abnormality was not a simple reciprocal translocation involving the regions of chromosomes 9p24 and 11q22, but an unbalanced chromosomal alteration due to the monoallelic loss of ATM and KMT2A genes. FISH continues to be considered an important technique for molecular investigation of small or hidden chromosomal abnormalities .
Taken together, the monoallelic deletions of the genes KMT2A and ATM, probably, contributed to the defects in the genomic instability of the chromatin remodeling, conferring a poor prognosis, being associated to a rapid leukemic transformation and a poor response to treatment. Furthermore, with our results we contribute to the literature showing an yet unreported der(9)t(9;11)(p24;q?22),der(11)t(9;11)(p24;q?22) with monoallelic loss of ATM and KMT2A genes.
This study was supported by the Brazilian Ministry of Health (National Institute of Cancer/INCA, Brazil) and CNPq.
Funding information is not applicable/No funding was received.
Availability of data and materials
Please contact author for data requests.
VLL participated in the design of the study and in manuscript writing. DCS conducted the conventional cytogenetic analyses and performed the FISH; TFA provided the revision of the myelogram and participated in manuscript writing. RRCM participated in manuscript writing. CD performed the immunophenotyping studies. The clinical history of the patient with MDS and AML was reviewed by MS. JCLJr performed the clinical history of the patient with FA and DEB analysis. MLMS, EA and TSF revised the manuscript critically for important intellectual content. The authors alone are responsible for the content and writing of the paper. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of the Brazilian National Cancer Institute (CEP #088/07). Written institutional informed consent for the participation of the patient in this study was obtained from the patient’s mother.
Consent for publication
The patient’s mother has given their institutional informed written consent for publication of the present case report.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 7.Ostra AB, Nieuwint AWM, Joenje H, Winter JP. Diagnosis of Fanconi Anemia: chromosomal breakage analysis. Anemia 2012; ID. 238731:1–9.Google Scholar
- 9.Auerbach AD. Diagnosis of Fanconi anemia by diepoxybutane analysis. Curr Protoc Human Genet. 2016;85:1–17.Google Scholar
- 20.McGowan-Jordan J, Simons A, Schmid M, editors. ISCN 2016: an international system for human cytogenetic nomenclature. Basel: Karger; 2016.Google Scholar
- 22.Huret JL, Ahmad M, Arsaban M, Bernheim A, Cigna J, Desangles F, et al. Atlas of genetics and cytogenetics in oncology and Heamatology 2013. Nucleic Acids Res. 2013 (Database issue):D920-4PMID:23161685.Google Scholar
- 24.Fuchs U, Borkhardt A. t(9;11)(q34;q23) FBP17/MLL. Atlas of Genetics and Cytogenetics in Oncology and Heamatology. 2001;5(3):200–201.Google Scholar
- 25.Huret, JL. t(9;11)(q34;p15). Atlas of Genetics and Cytogenetics in Oncology and Heamatology. 2005;9(1):32–33.Google Scholar
- 26.von Bergh ARM. t(9;11)(q34;q23)AF9q34/MLL. Atlas of Genetics and Cytogenetics in Oncology and Heamatology. 2006;10(1):22–23.Google Scholar
- 27.Morerio C; Panarello C. t(9;11)(p22;p15). Atlas of Genetics and Cytogenetics in Oncology and Heamatology. 2007;11(4):322–323.Google Scholar
- 28.Knijnenbug J, Beverloo HB. t(9;11)(p21;q23) KMT2A/MLLT3. Atlas of Genetics and Cytogenetics in Oncology and Heamatology. in press.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.